KRYS
Krystal BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
KRYS vs peer average
80/100
KRYS vs. peer average (A vs. C)
Grade spread
A 1 · B 3 · C 3 · D 2 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
CYTK is the first available peer comparator.
Cytokinetics is a more development-heavy biotech peer by market cap, but it lacks KRYS's approved gene-therapy commercial base, so read-through is mostly about pipeline valuation appetite rather than launch execution.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
KRYS
Krystal Biotech
CYTK
Cytokinetics
Grade
A
D
Momentum
82
85
Value
60
41
Sentiment
49
0
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs CYTK
KRYS / CYTK
Grade Position
Above peers
KRYS vs. peer average (A vs. C)
80/100
Momentum
82
CYTKValue
60
KRYSSentiment
49
KRYSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs KRYS
CYTK is the first peer returned for this comparison set.